{"id":78807,"date":"2026-09-04T16:52:17","date_gmt":"2026-09-04T08:52:17","guid":{"rendered":"https:\/\/flcube.com\/?p=78807"},"modified":"2026-09-04T16:52:19","modified_gmt":"2026-09-04T08:52:19","slug":"msds-keytruda-wins-nmpa-approval-for-perioperative-treatment-of-resectable-locally-advanced-hnscc-in-china","status":"publish","type":"post","link":"https:\/\/flcube.com\/?p=78807","title":{"rendered":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China"},"content":{"rendered":"\n<p class=\"wp-block-paragraph\"><strong>Merck &amp; Co., Inc. (MSD; <a href=\"https:\/\/www.google.com\/finance\/beta\/quote\/MRK:NYSE\">NYSE: MRK<\/a>)<\/strong> announced that its <strong>PD-1 inhibitor KEYTRUDA (pembrolizumab)<\/strong> has received approval from <strong>China\u2019s National Medical Products Administration (NMPA)<\/strong> as monotherapy for the <strong>neoadjuvant treatment<\/strong> of adult patients with <strong>resectable locally advanced head and neck squamous cell carcinoma (HNSCC)<\/strong> whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the <strong>first and currently only PD-1 inhibitor approved for the perioperative treatment<\/strong> of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.<\/p>\n\n\n\n<h2 id=\"h-regulatory-milestone\" class=\"wp-block-heading\">Regulatory Milestone<\/h2>\n\n\n\n<figure class=\"wp-block-table\"><table class=\"has-fixed-layout\"><thead><tr><th>Item<\/th><th>Detail<\/th><\/tr><\/thead><tbody><tr><td>Agency<\/td><td><strong>National Medical Products Administration (NMPA)<\/strong>, China<\/td><\/tr><tr><td>Approval Type<\/td><td>New indication approval<\/td><\/tr><tr><td>Product<\/td><td><strong>KEYTRUDA (pembrolizumab)<\/strong><\/td><\/tr><tr><td>Indication<\/td><td>Perioperative treatment of adult patients with resectable locally advanced <strong>HNSCC<\/strong>, PD-L1 positive (CPS \u22651) by validated test<\/td><\/tr><tr><td>Treatment Regimen<\/td><td>Neoadjuvant pembrolizumab monotherapy \u2192 adjuvant pembrolizumab + radiotherapy \u00b1 cisplatin \u2192 pembrolizumab monotherapy continuation<\/td><\/tr><tr><td>Date<\/td><td>03 Sept 2026<\/td><\/tr><tr><td>Distinction<\/td><td>First and only PD-1 inhibitor approved for perioperative resectable locally advanced HNSCC<\/td><\/tr><\/tbody><\/table><\/figure>\n\n\n\n<h2 id=\"h-drug-profile-amp-treatment-regimen\" class=\"wp-block-heading\">Drug Profile &amp; Treatment Regimen<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Molecule:<\/strong> <strong>pembrolizumab (KEYTRUDA)<\/strong>, a <strong>PD-1 inhibitor<\/strong> developed by <strong>Merck (MSD)<\/strong><\/li>\n\n\n\n<li><strong>Biomarker Requirement:<\/strong> Tumors must express <strong>PD-L1<\/strong> with a <strong>Combined Positive Score (CPS) \u22651<\/strong>, determined by a validated test<\/li>\n\n\n\n<li><strong>Approved Perioperative Regimen:<\/strong>\n<ul class=\"wp-block-list\">\n<li><strong>Neoadjuvant phase:<\/strong> Pembrolizumab monotherapy prior to surgery<\/li>\n\n\n\n<li><strong>Adjuvant phase:<\/strong> Pembrolizumab in combination with <strong>radiotherapy<\/strong>, with or without <strong>cisplatin<\/strong><\/li>\n\n\n\n<li><strong>Continuation phase:<\/strong> Pembrolizumab monotherapy<\/li>\n<\/ul>\n<\/li>\n\n\n\n<li><strong>Strategic Significance:<\/strong> The approval moves KEYTRUDA from the <strong>recurrent or metastatic<\/strong> HNSCC setting into the <strong>resectable locally advanced<\/strong> stage \u2014 earlier in the disease course where treatment intent is curative<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-clinical-amp-competitive-positioning\" class=\"wp-block-heading\">Clinical &amp; Competitive Positioning<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li>As the <strong>first and currently only PD-1 inhibitor<\/strong> approved for perioperative treatment of resectable locally advanced HNSCC, KEYTRUDA occupies an uncontested category in this indication<\/li>\n\n\n\n<li>The biomarker-selected, multi-phase regimen establishes a new treatment paradigm for a patient population historically managed with surgery and chemoradiotherapy alone<\/li>\n\n\n\n<li>The approval further expands KEYTRUDA\u2019s already broad footprint across head and neck cancer indications in China<\/li>\n<\/ul>\n\n\n\n<h2 id=\"h-market-impact-amp-outlook\" class=\"wp-block-heading\">Market Impact &amp; Outlook<\/h2>\n\n\n\n<ul class=\"wp-block-list\">\n<li><strong>Curative-intent expansion:<\/strong> Shifting immunotherapy into the resectable setting captures patients earlier, extending treatment duration and deepening KEYTRUDA\u2019s commercial footprint in HNSCC<\/li>\n\n\n\n<li><strong>First-mover moat:<\/strong> As the only approved PD-1 inhibitor in perioperative HNSCC, <strong>KEYTRUDA<\/strong> faces no direct immuno-oncology competition in this indication at launch<\/li>\n\n\n\n<li><strong>Biomarker-driven adoption:<\/strong> The CPS \u22651 requirement channels testing and diagnosis infrastructure, reinforcing companion diagnostic uptake alongside therapy adoption<\/li>\n\n\n\n<li><strong>Portfolio momentum:<\/strong> The approval strengthens <strong>MSD\u2019s<\/strong> (NYSE: MRK) oncology franchise in China, where perioperative immunotherapy is becoming a central battleground across solid tumor types<\/li>\n<\/ul>\n\n\n\n<p class=\"wp-block-paragraph\"><strong>Forward\u2011Looking Statements:<\/strong> This brief is for informational purposes only and does not constitute investment advice or an offer to buy or sell any security. Statements regarding drug commercialization, clinical adoption and market potential are forward-looking and subject to risks and uncertainties, including competitive developments, reimbursement outcomes and prescribing patterns. Actual results may differ materially. Readers should conduct their own due diligence before making investment decisions.<a href=\"https:\/\/flcube.com\/\">-Fineline Info &amp; Tech<\/a><\/p>\n","protected":false},"excerpt":{"rendered":"<p>Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has&#8230;<\/p>\n","protected":false},"author":1,"featured_media":78808,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"googlesitekit_rrm_CAownpewDA:productID":"","_jetpack_newsletter_access":"","_jetpack_dont_email_post_to_subs":false,"_jetpack_newsletter_tier_id":0,"_jetpack_memberships_contains_paywalled_content":false,"_jetpack_feature_clip_id":0,"_jetpack_memberships_contains_paid_content":false,"footnotes":"","jetpack_publicize_message":"","jetpack_publicize_feature_enabled":true,"jetpack_social_post_already_shared":true,"jetpack_social_options":{"image_generator_settings":{"template":"highway","default_image_id":0,"font":"","enabled":false},"version":2},"jetpack_post_was_ever_published":false},"categories":[7,11,4908],"tags":[16,120,2675,176,903,18,15],"class_list":["post-78807","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-company","category-drug","category-pic","tag-cancer","tag-merck","tag-merck-sharp-dohme","tag-msd","tag-nyse-mrk","tag-pd-1-l1","tag-product-approvals"],"yoast_head":"<!-- This site is optimized with the Yoast SEO Premium plugin v27.5 (Yoast SEO v28.4) - https:\/\/yoast.com\/product\/yoast-seo-premium-wordpress\/ -->\n<title>MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China - Insight, China&#039;s Pharmaceutical Industry<\/title>\n<meta name=\"description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China\u2019s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/flcube.com\/?p=78807\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China\" \/>\n<meta property=\"og:description\" content=\"Merck &amp; Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China\u2019s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/flcube.com\/?p=78807\" \/>\n<meta property=\"og:site_name\" content=\"Insight, China&#039;s Pharmaceutical Industry\" \/>\n<meta property=\"article:publisher\" content=\"https:\/\/www.facebook.com\/profile.php?id=61566606313834\" \/>\n<meta property=\"article:published_time\" content=\"2026-09-04T08:52:17+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2026-09-04T08:52:19+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp\" \/>\n\t<meta property=\"og:image:width\" content=\"1080\" \/>\n\t<meta property=\"og:image:height\" content=\"608\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/png\" \/>\n<meta name=\"author\" content=\"Fineline Cube\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:description\" content=\"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"Fineline Cube\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"3 minutes\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\\\/\\\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#article\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807\"},\"author\":{\"name\":\"Fineline Cube\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\"},\"headline\":\"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China\",\"datePublished\":\"2026-09-04T08:52:17+00:00\",\"dateModified\":\"2026-09-04T08:52:19+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807\"},\"wordCount\":488,\"commentCount\":0,\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0405.webp\",\"keywords\":[\"Cancer\",\"Merck\",\"Merck Sharp &amp; Dohme\",\"MSD\",\"NYSE: MRK\",\"PD-1\\\/L1\",\"Product approvals\"],\"articleSection\":[\"Company\",\"Drug\",\"PIC\"],\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"CommentAction\",\"name\":\"Comment\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78807#respond\"]}],\"copyrightYear\":\"2026\",\"copyrightHolder\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"}},{\"@type\":\"WebPage\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807\",\"url\":\"https:\\\/\\\/flcube.com\\\/?p=78807\",\"name\":\"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China - Insight, China&#039;s Pharmaceutical Industry\",\"isPartOf\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#primaryimage\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#primaryimage\"},\"thumbnailUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0405.webp\",\"datePublished\":\"2026-09-04T08:52:17+00:00\",\"dateModified\":\"2026-09-04T08:52:19+00:00\",\"description\":\"Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China\u2019s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.\",\"breadcrumb\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\\\/\\\/flcube.com\\\/?p=78807\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#primaryimage\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0405.webp\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2026\\\/09\\\/0405.webp\",\"width\":1080,\"height\":608,\"caption\":\"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China\"},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\\\/\\\/flcube.com\\\/?p=78807#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\\\/\\\/flcube.com\\\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#website\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"name\":\"Insight, China's Pharmaceutical Industry\",\"description\":\"Fineline Insights, Pharma Clarity\",\"publisher\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\\\/\\\/flcube.com\\\/?s={search_term_string}\"},\"query-input\":{\"@type\":\"PropertyValueSpecification\",\"valueRequired\":true,\"valueName\":\"search_term_string\"}}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#organization\",\"name\":\"Fineline Infomation and Technology\",\"alternateName\":\"Fineline Info & Tech\",\"url\":\"https:\\\/\\\/flcube.com\\\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\",\"url\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"contentUrl\":\"https:\\\/\\\/flcube.com\\\/wp-content\\\/uploads\\\/2024\\\/11\\\/Fineline-info-tech-scaled.jpg\",\"width\":2560,\"height\":1894,\"caption\":\"Fineline Infomation and Technology\"},\"image\":{\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/logo\\\/image\\\/\"},\"sameAs\":[\"https:\\\/\\\/www.facebook.com\\\/profile.php?id=61566606313834\"]},{\"@type\":\"Person\",\"@id\":\"https:\\\/\\\/flcube.com\\\/#\\\/schema\\\/person\\\/19ad11870d326204db8524d3c3c5e66a\",\"name\":\"Fineline Cube\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"url\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"contentUrl\":\"https:\\\/\\\/secure.gravatar.com\\\/avatar\\\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g\",\"caption\":\"Fineline Cube\"},\"sameAs\":[\"https:\\\/\\\/flcube.com\"],\"url\":\"https:\\\/\\\/flcube.com\\\/?author=1\"}]}<\/script>\n<!-- \/ Yoast SEO Premium plugin. -->","yoast_head_json":{"title":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China - Insight, China&#039;s Pharmaceutical Industry","description":"Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China\u2019s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/flcube.com\/?p=78807","og_locale":"en_US","og_type":"article","og_title":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China","og_description":"Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China\u2019s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.","og_url":"https:\/\/flcube.com\/?p=78807","og_site_name":"Insight, China&#039;s Pharmaceutical Industry","article_publisher":"https:\/\/www.facebook.com\/profile.php?id=61566606313834","article_published_time":"2026-09-04T08:52:17+00:00","article_modified_time":"2026-09-04T08:52:19+00:00","og_image":[{"width":1080,"height":608,"url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp","type":"image\/png"}],"author":"Fineline Cube","twitter_card":"summary_large_image","twitter_description":"Navigate the complexities of China\u2019s pharmaceutical industry with precision and clarity. FLCUBE delivers reliable data, news, and intelligence to broaden your horizons and sharpen your decision-making. Stay informed, stay ahead with FLCUBE.COM","twitter_misc":{"Written by":"Fineline Cube","Est. reading time":"3 minutes"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/flcube.com\/?p=78807#article","isPartOf":{"@id":"https:\/\/flcube.com\/?p=78807"},"author":{"name":"Fineline Cube","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a"},"headline":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China","datePublished":"2026-09-04T08:52:17+00:00","dateModified":"2026-09-04T08:52:19+00:00","mainEntityOfPage":{"@id":"https:\/\/flcube.com\/?p=78807"},"wordCount":488,"commentCount":0,"publisher":{"@id":"https:\/\/flcube.com\/#organization"},"image":{"@id":"https:\/\/flcube.com\/?p=78807#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp","keywords":["Cancer","Merck","Merck Sharp &amp; Dohme","MSD","NYSE: MRK","PD-1\/L1","Product approvals"],"articleSection":["Company","Drug","PIC"],"inLanguage":"en-US","potentialAction":[{"@type":"CommentAction","name":"Comment","target":["https:\/\/flcube.com\/?p=78807#respond"]}],"copyrightYear":"2026","copyrightHolder":{"@id":"https:\/\/flcube.com\/#organization"}},{"@type":"WebPage","@id":"https:\/\/flcube.com\/?p=78807","url":"https:\/\/flcube.com\/?p=78807","name":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China - Insight, China&#039;s Pharmaceutical Industry","isPartOf":{"@id":"https:\/\/flcube.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/flcube.com\/?p=78807#primaryimage"},"image":{"@id":"https:\/\/flcube.com\/?p=78807#primaryimage"},"thumbnailUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp","datePublished":"2026-09-04T08:52:17+00:00","dateModified":"2026-09-04T08:52:19+00:00","description":"Merck & Co., Inc. (MSD; NYSE: MRK) announced that its PD-1 inhibitor KEYTRUDA (pembrolizumab) has received approval from China\u2019s National Medical Products Administration (NMPA) as monotherapy for the neoadjuvant treatment of adult patients with resectable locally advanced head and neck squamous cell carcinoma (HNSCC) whose tumors express PD-L1 (CPS \u22651), followed by adjuvant treatment in combination with radiotherapy with or without cisplatin. As the first and currently only PD-1 inhibitor approved for the perioperative treatment of this disease, the approval extends KEYTRUDA\u2019s reach in HNSCC from the recurrent or metastatic setting into the curative-intent resectable stage.","breadcrumb":{"@id":"https:\/\/flcube.com\/?p=78807#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/flcube.com\/?p=78807"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/?p=78807#primaryimage","url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp","width":1080,"height":608,"caption":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China"},{"@type":"BreadcrumbList","@id":"https:\/\/flcube.com\/?p=78807#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/flcube.com\/"},{"@type":"ListItem","position":2,"name":"MSD\u2019s KEYTRUDA Wins NMPA Approval for Perioperative Treatment of Resectable Locally Advanced HNSCC in China"}]},{"@type":"WebSite","@id":"https:\/\/flcube.com\/#website","url":"https:\/\/flcube.com\/","name":"Insight, China's Pharmaceutical Industry","description":"Fineline Insights, Pharma Clarity","publisher":{"@id":"https:\/\/flcube.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/flcube.com\/?s={search_term_string}"},"query-input":{"@type":"PropertyValueSpecification","valueRequired":true,"valueName":"search_term_string"}}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/flcube.com\/#organization","name":"Fineline Infomation and Technology","alternateName":"Fineline Info & Tech","url":"https:\/\/flcube.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/","url":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","contentUrl":"https:\/\/flcube.com\/wp-content\/uploads\/2024\/11\/Fineline-info-tech-scaled.jpg","width":2560,"height":1894,"caption":"Fineline Infomation and Technology"},"image":{"@id":"https:\/\/flcube.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/profile.php?id=61566606313834"]},{"@type":"Person","@id":"https:\/\/flcube.com\/#\/schema\/person\/19ad11870d326204db8524d3c3c5e66a","name":"Fineline Cube","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","url":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/89f733aaed3d2d91d7d6f45d0e9ab509e3004e8243c6e57620b36380684657f2?s=96&d=mm&r=g","caption":"Fineline Cube"},"sameAs":["https:\/\/flcube.com"],"url":"https:\/\/flcube.com\/?author=1"}]}},"jetpack_publicize_connections":[],"jetpack_sharing_enabled":true,"jetpack_featured_media_url":"https:\/\/flcube.com\/wp-content\/uploads\/2026\/09\/0405.webp","_links":{"self":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78807","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcomments&post=78807"}],"version-history":[{"count":1,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78807\/revisions"}],"predecessor-version":[{"id":78811,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/posts\/78807\/revisions\/78811"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=\/wp\/v2\/media\/78808"}],"wp:attachment":[{"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fmedia&parent=78807"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Fcategories&post=78807"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/flcube.com\/index.php?rest_route=%2Fwp%2Fv2%2Ftags&post=78807"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}